Sagimet Biosciences Inc. Series A Common Stock (SGMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sagimet Biosciences Inc. Series A Common Stock (SGMT) has a cash flow conversion efficiency ratio of -0.085x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.18 Million) by net assets ($119.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sagimet Biosciences Inc. Series A Common Stock - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Sagimet Biosciences Inc. Series A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Sagimet Biosciences Inc. Series A Common for a breakdown of total debt and financial obligations.
Sagimet Biosciences Inc. Series A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sagimet Biosciences Inc. Series A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Capitan Mining Inc
V:CAPT
|
-0.065x |
|
Byggma
OL:BMA
|
-0.001x |
|
AFC Ajax NV
AS:AJAX
|
-0.092x |
|
Sabina Public Company Limited
BK:SABINA
|
0.078x |
|
Molecular Partners AG ADR
NASDAQ:MOLN
|
-0.104x |
|
Castles Technology Co Ltd
TW:5258
|
0.095x |
|
St.Shine Optical Co Ltd
TWO:1565
|
0.059x |
|
Finance of America Companies Inc
NYSE:FOA
|
-0.379x |
Annual Cash Flow Conversion Efficiency for Sagimet Biosciences Inc. Series A Common Stock (2019–2024)
The table below shows the annual cash flow conversion efficiency of Sagimet Biosciences Inc. Series A Common Stock from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see SGMT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $155.81 Million | $-42.44 Million | -0.272x | -4.36% |
| 2023-12-31 | $91.06 Million | $-23.77 Million | -0.261x | -299.22% |
| 2022-12-31 | $-186.95 Million | $-24.49 Million | 0.131x | -4.51% |
| 2021-12-31 | $-158.26 Million | $-21.71 Million | 0.137x | +79.00% |
| 2020-12-31 | $-135.91 Million | $-10.42 Million | 0.077x | -8.98% |
| 2019-12-31 | $-125.31 Million | $-10.55 Million | 0.084x | -- |
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associa… Read more